Analyses of methylation status and expression levels of RUNX1 in NSCLC patients reveal its potential clinicopathological significance, offering insights into its role as a diagnostic biomarker and a therapeutic target [59]. Here, RUNX1 is linked to non-small cell lung carcinoma.